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AbstrAct
Introduction Increasing physical activity (PA) reduces 
the risk of developing diabetes, highlighting the role 
of preventive medicine approaches. Changing lifestyle 
behaviours is difficult and is often predicated on the 
assumption that individuals are willing to change 
their lifestyles today to reduce the risk of developing 
disease years or even decades later. The self-monitoring 
technologies tested in this study will present PA feedback 
in real time, parallel with acute physiological data. 
Presenting the immediate health benefits of being more 
physically active may help enact change by observing the 
immediate consequences of that behaviour. The present 
study aims to assess user engagement with the self-
monitoring technologies in individuals at moderate-to-high 
risk of developing type 2 diabetes.
Methods and analysis 45 individuals with a moderate-
to-high risk, aged ≥40 years old and using a compatible 
smartphone, will be invited to take part in a 7-week 
protocol. Following 1 week of baseline measurements, 
participants will be randomised into one of three 
groups: group 1— glucose feedback followed by 
biobehavioural feedback (glucose plus PA); group 2—PA 
feedback followed by biobehavioural feedback; group 
3—biobehavioural feedback. A PA monitor and a flash 
glucose monitor will be deployed during the intervention. 
Participants will wear both devices throughout the 
intervention but blinded to feedback depending on group 
allocation. The primary outcome is the level of participant 
engagement and will be assessed by device use and 
smartphone usage. Feasibility will be assessed by the 
practicality of the technology and screening for diabetes 
risk. Semistructured interviews will be conducted to 
explore participant experiences using the technologies.
trial registration number ISRCTN17545949. Registered 
on 15/05/2017.
IntroductIon
There is widespread concern regarding the 
increasing prevalence of non-communi-
cable diseases such as type 2 diabetes.1 Type 
2 diabetes currently imposes an annual cost 
of £23.7 bn through its associated complica-
tions2; however, this cost is likely to rise as it is 
projected to directly impact 592 million indi-
viduals worldwide by 2035.3 Another imposing 
challenge is the proportion of the population 
living with undiagnosed diabetes (current prev-
alence estimated at 45.8%)4; which is possibly, 
in part, attributable to its asymptomatic state 
prior to the presentation of complications. 
Regardless of diagnosis status, preventing the 
development of type 2 diabetes is an interna-
tional priority moving forward.5 Pre-diabetes, 
categorised as either impaired fasting glucose 
or impaired glucose tolerance represents 
abnormal glucose homoeostasis and is placed 
between diabetes and normal regulation. 
Impaired fasting glucose has been defined as 
elevated fasting plasma glucose (100–126 mg/
dL) while impaired glucose tolerance is 
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Protocol
strengths and limitations of this study
 ► The study will present real-time biological and 
behavioural information to participants using 
wearable technologies; a novel concept which has 
not been used in physical activity research.
 ► The study will be the first to deploy flash glucose 
monitors to people at risk of developing type 2 
diabetes.
 ► A validated survey will be used to identify individuals 
at moderate-to-high risk of developing type 2 
diabetes, among which we expect a proportion to 
have pre-diabetes.
 ► While the duration of the intervention (six 
continuous weeks) will permit the examination of 
change in engagement over time, the absence of 
additional follow-ups prevents the assessment of 
long-term use engagement and behaviour change 
maintenance.
 ► Cost-effectiveness analysis will not be undertaken 
in this study.
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characterised by an elevated 2-hour plasma glucose concen-
tration (140–199 mg/dL) following intake of a 75 g glucose 
load.6 One in seven adults have impaired glucose regula-
tion7 and, compared with individuals living with normal-cir-
culating glucose levels, individual with pre-diabetes are 
5 to 10 times more likely to develop type 2 diabetes8 with 
5%–10% of people becoming diabetic annually.9 Diabetes is 
projected to be 1 of 10 leading causes of death worldwide10; 
thus, identification and prevention are crucial for early 
intervention. A lack of physical activity is considered one of 
the major risk factors for non-communicable diseases and 
is comparable to the ill-effects of obesity11 and smoking12 
individually. Given that physical inactivity, where insuffi-
cient levels of physical activity are achieved, is attributed to 
an estimated 7% of type 2 diabetes cases,13 it is an important 
modifiable lifestyle behaviour to target. With the preva-
lence of impaired fasting glucose doubling in individuals 
at 40–59 years and remaining consistent beyond 60 years,14 
targeting efforts towards specific age cohorts is crucial. Indi-
viduals with abnormal glucose homoeostasis are referred 
onto community-based lifestyle behaviour programmes 
such as The Healthier You: National Diabetes Prevention 
Programme (NDPP). Initiated in 2016, the programme 
aims to roll out nationally by 2020 as part of the National 
Health Service (NHS) Five Year Forward plan.15 The 
present study intends to implement a community screening 
approach, monitor participant retention and to investigate 
whether self-monitoring technologies providing feedback 
about physical activity and interstitial glucose levels play a 
role in the prevention pathway (which may be amenable to 
the NDPP framework).
With increasing recognition towards the integration of 
technology into usual care pathways (ie, emergence of NHS 
Digital), it is a crucial time to consider how technologies 
could contribute to the management of chronic diseases. 
Given recent consumer interest,16 wearable technolo-
gies permit people to self-monitor behaviour and health. 
Gardner and colleagues17 reviewed behavioural inter-
ventions and identified self-monitoring of behaviour as a 
particularly promising behaviour change technique. Simi-
larly, continuous glucose monitoring technology has shown 
promise for longer term physiological outcomes (including 
glycated haemoglobin (HbA1c)),18 supporting the sugges-
tion that more frequent engagement leads to better 
health outcomes.19 Self-monitoring of both behaviour and 
outcomes are listed within the taxonomy alongside 91 other 
ingredients (ie, feedback and goal setting) in behavioural 
interventions.20 As well as delivering key behaviour change 
techniques, self-monitoring technologies also support 
Control Theory.21 More specifically, people are presented 
with information about a present state via feedback (eg, 
9000 steps) and are often provided a set goal to achieve (ie, 
10 000 steps). Equipped with this information, people may 
make efforts to achieve the goal or desired outcome (ie, 
≥10 000 steps) because they have been informed how they 
are performing relative to it. The majority of research to date 
has focused on the deployment of technologies to self-mon-
itor movement behaviours22 or specific health markers23 
in isolation. Although these approaches have shown to be 
beneficial to behaviour change in the short term, most user 
engagement is not sustained beyond 6 months.24 Despite 
research conducted on short-term improvements, it is 
not yet clear whether results are sustained with prolonged 
use.25 26 However, the rationale is that when provided with 
information about their current levels of activity, people 
may feel motivated to improve their behaviour.
With a view to sustaining the ‘honeymoon period’ of 
technology-bolstered behaviour change, a logical next step 
would be to deploy wearable technologies in combina-
tion. For example, studies investigating the acute effects of 
brief physical activity bouts or interruptions to prolonged 
sedentary behaviour on glucose levels in controlled settings 
have found reductions in postprandial glucose as a result 
of increased movement.27–30 As a result, the present study 
proposes that delivering behavioural and physiological 
feedback in parallel may be more persuasive rather than 
when delivered in isolation. This approach may offer a plat-
form for people to self-educate themselves about the rela-
tionship between movement and acute health status (ie, 
walking after a meal leads to marked reductions in glucose 
levels); which may help sustain engagement with self-mon-
itoring technologies. With ongoing developments, tech-
nologies such as flash glucose monitoring offer a wealth of 
information to users without the need for invasive finger-
prick samples; offering a useful tool for individuals without 
diabetes (who are not accustomed to regular fingerprick 
blood samples).31 To date, an important limitation of the 
efforts to encourage people to be more physically active has 
been the assumption that we are willing to change our life-
styles today to reduce our risk of developing disease years 
or even decades later. Implementing specific behaviour 
change techniques such as self-monitoring, goal setting and 
feedback,20 wearable devices could empower individuals 
to manage their health through a change in behaviour by 
recognising movement patterns and observing influences 
on health. Building on previous findings which observed 
greater levels of brain activation in response to personalised 
glucose-related information (over behavioural informa-
tion) (Whelan et al, submitted), the present study aims to 
examine the role of providing novel self-monitoring tech-
nologies presenting biobehavioural feedback in those living 
at moderate-to-high risk of type 2 diabetes.
AIMs And objectIves
Primary aim
The primary aim of this study is to investigate participant 
engagement using self-monitoring technologies for phys-
ical activity and interstitial glucose.
secondary aims
The secondary aims of this study are to explore (1) the 
feasibility of the intervention trial at baseline, 1, 2, 3, 4, 5 
and 6 weeks; (2) levels of physical activity and interstitial 
glucose levels at baseline, 1, 2, 3, 4, 5 and 6 weeks and 
(3) levels of technology readiness, health literacy, health 
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Figure 1 An illustration of the intervention design (*indicates a brief appointment at 4 weeks).
status and attitudes towards one’s own health at baseline 
and post self-monitoring.
Methods And AnAlysIs
study setting
Participants will be recruited from the community in 
Leicestershire, UK from May to November 2017. All 
appointments (three or four in total, depending on group 
allocation) will take place at the National Centre for Sport 
and Exercise Medicine at Loughborough University, UK.
study design
The feasibility study protocol has been prepared in accor-
dance with the Standard Protocol Items: Recommen-
dations for Interventional Trials32 with reference to the 
Template for Intervention Description and Replication33 
(see online supplementary file 1) .
The study will aim to recruit 45 individuals with 15 
participants randomly allocated to each of the three 
groups. No specific sample size has been calculated due 
to its feasibility status but study results will inform the 
sample size for a full-scale intervention.
The Sensing Interstitial Glucose to Nudge Active 
Lifestyle study will last 7 weeks in total and is outlined 
in figure 1. Following baseline (1 week), participants 
will be randomised into one of three groups. Partici-
pants will be notified of their group allocation at the 
second appointment before starting the intervention 
period. Appointments will be arranged at the preceding 
appointment where possible. The study was registered 
on the International Standard Randomised Controlled 
Trial number (ISRCTN) Register (ISRCTN17545949) in 
May 2017.
randomisation
Participants will be block randomised using a 1:1:1 study 
allocation ratio, coordinated by a remote internet-based 
service (http://www. sealedenvelope. com/). Randomis-
ation will be done by a member of the research group, 
independent to the present study. Baseline measures will 
be conducted prerandomisation. Participants will be noti-
fied of their group allocation at appointment 2. In the 
event of participants originating from the same house-
hold, identical group allocation will be employed to avoid 
any cross-contamination.
Inclusion criteria
Participants will be at least 40 years old, be at moderate-
to-high risk of developing type 2 diabetes34 and use a 
compatible Android smartphone.
Compatible smartphones at the time of the study will 
be defined as having the following characteristics: an 
Android operating system of 4.0 or higher, Near Field 
Communication (NFC), a screen resolution of 480×800 to 
1080×1920 and a screen size of 8.9–14.5 cm. Exceptions at 
the time of the study are the Samsung Galaxy 7, Samsung 
S8, Nexus 5X and Nexus 6P which cannot install the 
LibreLink application.
exclusion criteria
Individuals with a clinical diagnosis of type 1 or type 
2 diabetes, an HbA1c of ≥6.5% or have suspected/
confirmed pregnancy will be excluded. Participants 
unable/unwilling to provide informed consent, cannot/
unwilling to adhere to the study protocol or cannot read/
write English will also be excluded.
recruitment procedure
Participants will be recruited at community sites through 
the distribution of posters and leaflets in community 
organisations and local businesses based in Leicester-
shire, UK. Individuals will also be recruited through an 
existing Movement Insights Lab participant database. All 
individuals will be directed to complete a brief survey to 
determine level of risk for type 2 diabetes. Participant 
information sheets will be provided (copies available on 
request). The questions will be presented via an online 
survey platform (Qualtrics, Provo, Utah, USA) and 
will relate to gender, age, ethnic background, familial 
history of diabetes, waist circumference, body mass index 
(BMI) and blood pressure. The validated survey34 has 
been used in studies applying risk score algorithms on 
primary care electronic data.35 Waist circumference will 
be replaced with clothing size and fit following guidance 
offered by Battram and colleagues.36 Moderate-to-high 
risk individuals will be contacted by the research team to 
take part in the study. Ineligible individuals (ie, low risk, 
increased risk or a moderate/high risk, but are not aged 
at least 40 years old nor use an Android smartphone) 
will be directed to Diabetes UK ‘Type 2 diabetes: What 
to do if you’re at risk’ information booklets (available 
at: https://www. diabetes. org. uk/ Global/ professionals/ 
KYR% 20Booklet. pdf).
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study Procedure
First appointment and baseline
An outline of the study procedure is presented in 
figure 1. Appointment one will involve informed consent, 
health measures (height, weight, percentage body 
fat, waist circumference, blood pressure, HbA1c, grip 
strength, quadriceps strength and aerobic fitness; full 
methodological details are provided in the measures 
section below) and a brief demographics questionnaire. 
Participants will complete a physical activity readiness 
questionnaire37 before completing the aerobic fitness 
assessment for screening purposes. Participants will be 
fitted with a waist-worn accelerometer and a wrist-worn 
activity tracker. Neither device will provide feedback to 
the participant during the seven consecutive days of wear. 
Participants will be asked to install two mobile applica-
tions onto a personal Android smartphone. Both smart-
phone applications will sit idle on the smartphone for the 
duration of baseline. Participants will be asked to sync the 
activity tracker via the smartphone application; switching 
on Wi-Fi and Bluetooth simultaneously at least once every 
5 days for ≥1 hour to ensure the sync occurs.
second appointment and intervention
One week later (following baseline), participants will 
attend appointment 2 where they will be informed of their 
group allocation. Participants will be asked to complete 
a brief questionnaire to continue wearing the activity 
tracker during the intervention (settings may or may not 
be adjusted) and to return the accelerometer. A glucose 
sensor will be deployed to each participant to measure 
interstitial glucose levels. Participants will be provided 
with additional supplies of glucose sensors to last for 
the four (groups 1 and 2) or six weeks (group 3) of the 
intervention. Accounts for both the activity tracker and 
glucose sensor will be connected to Diasend (Diasend, 
Chicago, Ilinois, USA). An overview of the three groups 
is provided below.
Group 1 (glucose feedback followed by biobehavioural feedback)
Real-time interstitial glucose feedback will be presented 
to participants for 4 weeks via the LibreLink applica-
tion (Abbott Diabetes Care, Alameda, California, USA). 
Participants will install the LibreLink mobile application 
(Abbott Diabetes Care, Alameda, California, USA) onto 
a personal Android smartphone to interact with the 
Freestyle Libre via NFC for measurement of interstitial 
glucose. The glucose monitor has a lifespan that restricts 
wear to 14 consecutive days. The application will remind 
participants to scan every 7 hours and to remove/replace 
after 14 days. The LibreLink application will continuously 
display the number of days left.
Group 2 (physical activity feedback followed by biobehavioural 
feedback)
Real-time physical activity feedback will be presented for 
4 weeks via the Fitbit application. In contrast to group 
1, participants will not have the LibreLink application 
installed and so will not have access to glucose feedback. 
Participants will be informed that the glucose sensor is 
functional (recording data) and participants will be asked 
to remove and replace the expired sensor with another 
sensor after 14 days.
Device unmasking for groups 1 and 2 after 4 weeks
At the end of the first 4 weeks of the intervention, partic-
ipants in groups 1 and 2 will attend a brief appointment 
(up to 1 hour in duration). For group 1, the researcher 
will adjust settings to reveal physical activity feedback 
via the Fitbit application and device. For group 2, the 
researcher will install the LibreLink application to reveal 
glucose feedback. All participants will be able to access 
biobehavioural feedback for the remaining 2 weeks of the 
intervention.
Group 3 (biobehavioural feedback)
Participants in group 3 will receive biobehavioural 
feedback for the full 6 weeks via the two independent 
LibreLink and Fitbit applications. Participants will 
install the LibreLink mobile application onto a personal 
Android smartphone to interact with the Freestyle Libre 
to measure interstitial glucose. The application will 
remind participants to scan every 7 hours and to remove/
replace the sensor after 14 days.
Final appointment
All participants (groups 1, 2 and 3) will be asked to attend 
the final appointment at the end of the intervention 
where they will complete a questionnaire (identical to 
appointment 2, apart from the revised Diabetes Knowl-
edge Test) and a semistructured interview. All participants 
will also receive a personalised health report containing 
results from the health measures conducted at appoint-
ment one.
device masking
All email accounts and password combinations will be 
manually generated and managed by the research team to 
prevent use of identifiable information. During baseline 
wear, the activity tracker will be physically masked using 
black tape applied to the screen; leaving only time and 
date viewable. Participants will be asked not to tamper with 
the screen; however, if they do manipulate the masking, it 
should be readily apparent to the research team. Settings 
on the application will also be adjusted to remove phys-
ical activity metrics from the device screen and notifica-
tions fully restricted on their phone and activity tracker. 
However, participants will not be locked out of the appli-
cation due to the requirement to sync the device. Time 
spent on the Fitbit application will be inspected using 
Ethica Data (Kitchener, Ontario, Canada) to identify 
potential unauthorised use. The activity tracker will also 
be set to all-day sync to minimise data loss with data auto-
matically transferred (Wi-Fi and Bluetooth must both be 
simultaneously switched on). When required to prevent 
access to glucose feedback, participants will wear the 
glucose sensors for 14-day period as normal but will not 
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be asked to install the LibreLink application nor scan the 
sensor (ie, no data will be collected). This will standardise 
wear across all three groups.
data management and storage procedures
All data collected will be anonymised by assigning a partic-
ipant identification. Accounts with the three applications 
(Fitbit, LibreLink and Ethica Health) will be setup using 
study-specific (‘dummy’) email addresses and passwords 
(accessible only to the research team) to minimise use of 
personalised information. All data will be stored securely 
on the Loughborough University server, as password-pro-
tected, encrypted documents and original paperwork 
kept in locked storage. No directly personally identifiable 
information will be collected through these platforms. 
Global positioning system (GPS) will be collected via 
Ethica Data which could theoretically be ‘reverse-engi-
neered’ to reidentify individuals; however, all participants 
will be explicitly informed about all information moni-
tored as part of the study. For individuals who do not wish 
to have their location services monitored, we will set up 
a ‘reduced access’ version of Ethica Data (application 
usage, screen state and survey responses only).
PrIMAry outcoMes
user engagement: Quantitative
Time spent on the official free Fitbit and LibreLink appli-
cations will be quantified using Ethica Data as well as time-
stamped data relating to when the smartphone screen was 
turned on and off. In combination, these two data sources 
will reveal the proportion of time that the devices’ applica-
tions were used in relation to total smartphone use. These 
data will be recorded at either a day level (eg, aggregate 
time) or event level (eg, record of each time an applica-
tion was opened) depending on the Android smartphone 
model. How often and how much time spent on the two 
applications compared with other applications on partic-
ipants’ smartphones will also be quantified. Number of 
times the activity tracker syncs (occurs when the applica-
tion is opened, assumed to see feedback about physical 
activity) and scans of the glucose sensor (occurs when the 
participant scans and to see feedback about interstitial 
glucose levels) will also be recorded. Compulsory engage-
ment will be participants having to sync the activity tracker 
at least once every 5 days and scan the glucose sensors at 
least once every 7 hours. The number of syncs and scans 
recorded over and above compulsory engagement will 
reflect optional engagement. Identifying when and how 
often syncs and scans happen and how these patterns 
change over the course of the intervention (from week 
1 to 6) will indicate engagement with the technology. We 
will also identify if participants change the goal settings 
relating to steps, floors climbed and active minutes on 
the Fitbit application. These settings will be checked daily 
between the hours of 18:00-19:00 by the research team 
and changes will be flagged with details of the original 
and new setting logged. In addition, assessing whether 
participants responded to prompts offered by the activity 
tracker will also be conducted (ie, did participants achieve 
250 steps/hour? See Behaviour Change Techniques 
section for further detail).
Remote monitoring of participant glucose and phys-
ical activity will be completed using Diasend and Fitabase 
(Small Steps Labs LLC, San Diego, California, USA), 
respectively. Diasend will connect with the Freestyle Libre 
via the LibreLink application and data will be recorded 
and accessed through this software. Additional data 
sources to be monitored by Ethica Data include battery 
status (ie, smartphone plugged in? Charging?), Blue-
tooth and Wi-Fi (turned on or off). Quantifying these 
data sources will provide valuable insight into partici-
pant behaviour (eg, Do participants only use Wi-Fi and 
Bluetooth for the purpose of our intervention? Are 
participants charging it more often in the intervention 
compared with baseline?). Ethica Data will also monitor 
location (GPS), motion (pedometer, accelerometer, 
gravity, gyroscope, linear acceleration, magnetic field, 
orientation) and survey responses. These digital streams 
will monitor smartphone usage and will provide detailed 
data on human behaviour during a free-living, naturalistic 
setting. In total, 14 data sources will be monitored. In the 
event a participant raises concerns relating to the number 
and/or type of data sources being monitored, a restricted 
coverage option of only three data sources (application 
usage, screen state and survey responses) will be offered.
user engagement: qualitative
For participants who complete the 6-week intervention, a 
semistructured interview will be completed (20–40 min) 
during the final appointment at the National Centre for 
Sport and Exercise Medicine, Loughborough University, 
UK. The interview will aim to identify potential barriers 
and facilitators to using self-monitoring technologies. In 
particular, how participants experience receiving feed-
back relating to physical activity and interstitial glucose 
levels. These interviews will explore individual experi-
ences using the device(s) and mobile application(s), 
adherence to syncing (Fitbit) and scanning (Freestyle 
Libre), wearing multiple devices and the perceived 
effect of viewing feedback on actual behaviour. In addi-
tion, participants will be asked about future intentions 
to continue wearing self-monitoring devices and identify 
any recommended changes for future study designs.
If a participant decides to withdraw from the study at 
any time prior to the final appointment, they will be able 
to leave the study via (1) the Ethica Health application 
on their personal smartphone (aligning with a dynamic 
consenting process38) or by (2) contacting the research 
team via telephone or email. Participants that decide to 
withdraw via Ethica Health will be directed to complete 
a brief exit survey on the application. The research team 
will contact all participants for an optional exit interview 
(5–10 min) via telephone. This will be recorded using 
Tapeacall (http://www. tapeacall. com/) and will explore 
reasons for not completing the study.
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Table 1 An overview of the feasibility components to be assessed
Feasibility component Data source (indicator of feasibility)
Practicality of technology/
intervention
 ► Qualitative interviews
 ► Fitabase (sync compliance, missing data and response to haptic prompt)
 ► LibreLinkUp (scan compliance)
 ► Diasend (missing data, identification of glucose sensor sensor-related issues)
 ► Project records (identification of need to dispatch additional glucose sensors, number of 
individuals screened, rate of eligibility, study uptake and retention)
 ► Ethica data (data sources, enrolment into full* or restricted† coverage)
Acceptability of 
technology/intervention
 ► Qualitative interviews
 ► Fitabase (activity tracker wear time)
 ► Diasend (glucose sensor wear time, digital footprint of time taken to move onto the next glucose 
sensor that is, sensor delay?)
 ► Project records (changes to goal settings, manual withdrawals, attendance at appointments, 
retention to follow-up)
 ► Ethica data (digital footprint of application usage, Bluetooth and Wi-Fi status, battery status, 
electronic withdrawal)
*Full coverage: application usage, screen state, Bluetooth, Wi-Fi, GPS, pedometer, accelerometer, gravity, gyroscope, linear acceleration, 
magnetic field, orientation, battery and survey responses.
†Restricted coverage: application usage, screen state and survey responses.
GPS, global positioning system
secondAry outcoMes
Feasibility
Guidelines used to assess the feasibility of this study 
were informed by Bowen and colleagues.39 Both qual-
itative and quantitative data will be collected to assess 
feasibility of deploying novel self-monitoring technolo-
gies in parallel. In total, we will assess intervention feasi-
bility as outlined in table 1.
Physical activity levels
ActiGraph
In an effort to determine the physical activity levels of 
the participants relative to general population, partic-
ipants will be asked to wear an ActiGraph wGT3X-BT 
(ActiGraph, Pensacola, Florida, USA) accelerometer for 
7 days during waking hours and to remove for any water-
based activities (eg, showering and swimming). The 
waist-worn (ie, over the right hip, midclavicular line) 
ActiGraph will quantify time spent sedentary, in light 
and moderate-to-vigorous physical activity (MVPA) as 
well as daily step counts and will function as a data logger 
(ie, no feedback provided). ActiGraph accelerometers 
have been validated40 41 and extensively deployed42–44 to 
measure physical activity under free-living conditions. 
Data from the ActiGraph will be collected at 100 Hz and 
integrated into 60 s epochs using ActiLife (ActiGraph, 
Pensacola, Florida, USA) and processed using Kine-
soft (Kinesoft, Loughborough, UK). Non-wear will be 
defined as 60 min of consecutive zeros (allowing for up 
to 2 min of interruptions) with a minimum wear of 600 
waking minutes used to define a valid day.43 A minimum 
of four valid days will be used to define a valid file with 
sedentary time classified as <100 cpm, light activity as 
100-2019 cpm and MVPA as >=2020 cpm.43
Fitbit
The Fitbit Charge 2 (Fitbit, San Francisco, Cali-
fornia, USA) will be worn on the wrist associated with 
the non-dominant arm and, while being sweat, rain and 
splash proof, participants will be asked to remove the 
device for water-based activities. The Fitbit records inten-
sity (ie, minutes spent lightly active, fairly active and very 
active) in addition to heart rate and step count. Heart 
rate will be assessed using Fitbit’s proprietary PurePulse 
optical heart rate technology. To examine changes in 
physical activity over the study duration, participants will 
be requested to wear the device for the full 7 weeks and 
data will be analysed in 60 s epochs following export from 
Fitabase. Previous models of the Fitbit have been vali-
dated for step count.45 A waking protocol will be imple-
mented with non-wear defined as a loss of a heart rate 
signal. Participants will be requested to sync the Fitbit at 
least once every 5 days (rather than the company recom-
mendations of 7 days) to minimise data loss. Syncs beyond 
7 days will result in day level data rather than minute level 
data. These syncs will either occur automatically (ie, 
without the application open) or will be user driven (ie, 
with the application open) depending on how the all-day 
sync is set and heart rate will be set to automatic (only 
record heart rate when device is worn).
Interstitial glucose levels
Freestyle Libre
The minimally invasive Freestyle Libre flash glucose 
monitor (Abbott Diabetes Care, Alameda, California, USA) 
will be covered with Tegaderm (3M Health Care, St Paul, 
Minnesotta, USA) to help maintain position and adhe-
sion during the 14-day sensor life span. Three strips of 
Tegaderm will be provided to participants per sensor to 
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Figure 2 A schematic of how the wearable technologies, mobile applications and software connect.
allow for replacement when the Tegaderm becomes dirty. 
Participants will be asked to wear the device continuously 
without removal for water-based activities. The Freestyle 
Libre demonstrates consistent accuracy throughout the 
14 days with a mean absolute relative difference of 11.4% 
compared with capillary blood glucose, a lag time of 
4.5–4.8 min and is not impacted by physical characteris-
tics including age, BMI and HbA1c.31 Participants will be 
requested to scan the glucose monitor at least once every 
7 hours (rather than the company recommendations of 
8 hours) to minimise data loss. If participants experience 
skin irritation on the non-dominant arm in the region 
of application, participants will be advised to switch to 
their dominant arm. Interstitial glucose data will be 
downloaded in 15 min epochs using Diasend, an online 
platform connected to the LibreLink application. Partic-
ipant accounts will be linked to Diasend from the point 
of LibreLink application installation. Figure 2 illustrates 
how the numerous components connect to achieve the 
primary and secondary aims.
levels of technology readiness, health status and attitude
All questionnaires will be completed electronically using 
an online platform for immediate data entry (http://
www. onlinesurveys. ac. uk/; Bristol, UK). At appointment 
2, quality of life will be assessed via the 26-item  EuroQoL 
5 Dimensions 5 Levels,46 technology readiness via the 
16-item Technology Readiness Index V. 2.0,47 health 
literacy via the eight-item eHealth Literacy Scale,48 
diabetes knowledge via the 20-item revised diabetes 
knowledge test49 and general attitude towards developing 
diabetes via the eight-item general attitudes section of the 
Risk Perception Survey for Developing Diabetes.50
other MeAsures
Participant characteristics
Self-reported age, sex, ethnic background, employ-
ment, household income, postcode (to provide an Index 
of Multiple Deprivation score) and education will be 
recorded.
health, physical functioning and fitness
HbA1c will be assessed at the first appointment using a 
point-of-care system, (Afinion AS100 Analyser, Alere, 
Waltham, Massachusetts). Results will be processed 
immediately following collection. Participants receiving 
a result ≥6.5% will be ineligible, readings of 5.7%–6.4% 
classified as with pre-diabetes51 and readings of <5.7% 
classified as euglycaemic. A measure of height will be 
conducted using a Seca stadiometer (Seca, Hamburg, 
Germany) and weight and body fat percentage will 
be measured using Tanita scales (Tokyo, Japan). Two 
measures of waist circumference will be taken at the 
midpoint between the lowest rib and top of the iliac crest; 
if the difference exceeds 1 cm, the two measurements 
will be repeated.52 Three measures of blood pressure will 
be recorded using an Omron digital monitor (Omron, 
Kyoto, Japan) with the first measure taken after the partic-
ipant has remained seated for 10 min. Grip strength will 
be assessed using a handheld Takei dynamometer (Takei 
Scientific Instruments, Tokyo, Japan) while standing with 
hands positioned down each side. Quadriceps strength 
will be assessed using the DAVID G200 knee extension 
machine (David Health Solutions, Helsinki, Finland). 
Aerobic fitness will be assessed using the modified Cana-
dian Aerobic Fitness Test (mCAFT).53 The mCAFT is a 
submaximal step-test protocol with participants instructed 
to complete ≥1 3-min stages of stepping at a speed 
dictated by an audio track. Heart rate will be monitored 
throughout with the stepping stages continued until heart 
rate ≥85% of age-predicted maximal heart rate. Partici-
pants’ scores for aerobic fitness will be defined according 
to the following formula: 10*[17.2 + (1.29×oxygen cost 
at the final stage) - (0.09×weight in kg) - (0.18×age in 
years)].53
behaviour change techniques
Prior to starting the intervention, the researcher will 
implement the default settings for levels of physical 
activity (behaviour change technique (BCT) 1.1: goal 
setting (behaviour)) (ie, 10 000 steps and 10 floors 
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climbed) and glucose (BCT 1.3: goal setting (outcome)) 
(ie, 4.0–5.9 mmol/L). Participants will be fully informed 
that they can freely change the goals set for physical 
activity as preferred (ie, should the default value be 
too easy/difficult) via the Fitbit application. However, 
participants will be advised to not make any changes via 
the LibreLink application for the target glucose range. 
Attainment of a goal will be assessed as either complete 
or incomplete. Participants will be asked to sync the Fitbit 
(at least once every 5 days) and scan the Freestyle Libre 
(at least once every 7 hours) if they are in the respec-
tive group to receive feedback from these devices. This 
action has a dual purpose; to minimise data loss and to 
encourage continued engagement with the technologies. 
Participants will also receive haptic feedback (BCT 7.1: 
prompts/cues; ie, a gentle vibration) as a reminder to 
move by the Fitbit 10 min prior to the end of each hour 
(default 09:00-18:00) if 250 steps have not been taken. The 
reminder to move prompt aims to encourage interrup-
tions in prolonged sedentary bouts as is recommended 
by the UK Physical Activity Guidelines.54 In relation to 
the other behaviour change techniques, participants 
will be able to monitor physical activity levels using the 
Fitbit Charge 2 (BCT: 2.3: self-monitoring of behaviour) 
and glucose levels using the Freestyle Libre (BCT: 2.4: 
self-monitoring of outcome(s) of behaviour) which is a 
minimally invasive device that presents feedback about 
glucose (BCT: biofeedback).
QuAntItAtIve dAtA AnAlysIs
Analysis of primary outcomes
Ethica Data is a fee-for-service platform that will be used to 
provide time-stamped data relating to application usage. 
This is an application installed on participants’ phones 
and sits idle during the study period. The number of scans 
and syncs will be unobtrusively assessed using the free 
LibreLinkUp mobile application (Abbott Diabetes Care, 
Alameda, California, USA) and Fitabase, respectively. 
Fitabase is a fee-for-service platform that permits access 
to download 60 s epoch Fitbit data (ie, levels of physical 
activity) and remote monitoring of Fitbit devices (eg, 
battery level and time since last sync event) via Bluetooth 
and Wi-Fi. Identification of moments where participants 
have decided to change the goal settings will be completed 
by accessing the online Fitbit account. The researchers 
will remotely access participants’ accounts daily between 
18:00 and 19:00 to note goal settings; recording the date 
and live/current settings for all metrics (eg, step count) 
to help identify any changes.
Analysis of secondary outcomes
To assess eligibility, uptake and retention, we will manu-
ally record how many individuals complete the screening 
survey, how many meet our inclusion criteria and of these 
how many decide to enrol. In addition, the screening 
survey will also identify recruitment sources. Identifying 
non-usage attrition and dropout attribution is crucial to 
assess the feasibility of an intervention as they are both 
important but distinct constructs.55 Non-usage attrition, 
where participants have disengaged from the interven-
tion but have not dropped out, will be defined as partic-
ipants who attend appointment 2 but do not sync the 
Fitbit or scan the Freestyle Libre. Dropout attrition will be 
defined as participants who explicitly withdraw from the 
study via Ethica Health or direct contact with the research 
team. The number of participants who enrol into the full 
coverage (all 14 data sources monitored) or restricted 
coverage (only three data sources monitored) for Ethica 
Data will also be recorded. Diasend is a fee-for-service 
platform that permits access to download 15 min epoch 
data from the Freestyle Libre and remote monitoring of 
multiple LibreLink accounts. Descriptive statistics of the 
sample will be conducted. In addition, two-way repeated 
measures analyses of covariances (ANCOVAs) will be 
conducted to assess changes in engagement (dependent) 
according to group (independent) having adjusted for 
participant characteristics. Similarly, two-way repeated 
measures ANCOVAs will be conducted to assess changes 
in physical activity (dependent) according to group (inde-
pendent) having adjusted for baseline physical activity, 
Fitbit wear time and participant characteristics. All data 
will be analysed using SPSS Version 24.0).
QuAlItAtIve dAtA AnAlysIs
All interviews will be audiorecorded (with informed 
consent), transcribed verbatim and analysed using 
thematic analysis. This will involve standard thematic 
data analysis procedures; identifying emerging patterns 
in the interview.56 Transcripts will be analysed using 
constant comparison with initial free coding and emer-
gent themes interrogated.57 The interview schedule and 
coding schedule will be modified to follow new leads until 
new themes no longer emerge. The analysis will create 
a coding frame that ‘fits’ the data.57 Transcripts will be 
uploaded into NVivo qualitative data analysis software 
(QSR International).
dissemination
This work will inform a full-scale randomised-controlled 
trial (RCT) by enabling a sample size calculation. The 
full-scale RCT will primarily aim to investigate changes 
in physical activity and interstitial glucose levels in indi-
viduals randomised into the three groups. Overall, the 
findings seek to encourage the implementation of tech-
nologies into usual preclinical care pathways; in partic-
ular, how engaging with self-monitoring technologies 
(providing biobehavioural feedback) may positively influ-
ence rates of uptake, adherence, retention and behaviour 
change.
We will publicise study findings online, present them 
at international conferences relating to diabetes, physical 
activity and digital health and publish via a peer-reviewed 
journal.
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